Skip to main content

Peer Review reports

From: Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study

Original Submission
12 Jul 2023 Submitted Original manuscript
12 Oct 2023 Reviewed Reviewer Report
19 Oct 2023 Reviewed Reviewer Report
6 Dec 2023 Author responded Author comments - Yuankai Shi
7 Dec 2023 Author responded Author comments - Yuankai Shi
Resubmission - Version 2
6 Dec 2023 Submitted Manuscript version 2
13 Dec 2023 Author responded Author comments - Yuankai Shi
Resubmission - Version 3
13 Dec 2023 Submitted Manuscript version 3
14 Dec 2023 Author responded Author comments - Yuankai Shi
Resubmission - Version 4
14 Dec 2023 Submitted Manuscript version 4
25 Dec 2023 Reviewed Reviewer Report
30 Dec 2023 Reviewed Reviewer Report
8 Jan 2024 Author responded Author comments - Yuankai Shi
Resubmission - Version 5
8 Jan 2024 Submitted Manuscript version 5
10 Jan 2024 Author responded Author comments - Yuankai Shi
Resubmission - Version 6
10 Jan 2024 Submitted Manuscript version 6
Publishing
13 Jan 2024 Editorially accepted
24 Jan 2024 Article published 10.1186/s12885-024-11876-9

You can find further information about peer review here.

Back to article page